Track market-moving stories before they get noisy

New Jersey Resources is executing a clean energy pivot, allocating over 60% of $4.8–$5.2 billion CapEx through FY2030 to solar-focused Clean Energy Ventures. NJR delivered strong winter-driven Q2 results, beating non-GAAP EPS by $0.30 and revenue by nearly 10%, and raised full-year non-GAAP EPS guidance to $3.48–$3.62. Despite robust operating cash flow growth, NJR's high CapEx outpaces cash generation, requiring increased debt while targeting a 20% adjusted debt-to-capital ratio.

A strong stock as of late has been New Jersey Resources (NJR - Free Report) . Shares have been marching higher, with the stock up 3.3% over the past month. The stock hit a new 52-week high of $57.91 in the previous session. New Jersey Resources has gained 25.3% since the start of the year compared to the 6.9% move for the Zacks Utilities sector and the 5.8% return for the Zacks Utility - Gas Distribution industry.

What's Driving the Outperformance?The stock has a great record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on May 4, 2026, New Jersey Resources reported EPS of $2.2 versus consensus estimate of $1.89.

For the current fiscal year, New Jersey Resources is expected to post earnings of $3.45 per share on $2.21 in revenues. This represents a 5.5% change in EPS on a 8.54% change in revenues. For the next fiscal year, the company is expected to earn $3.47 per share on $2.36 in revenues. This represents a year-over-year change of 0.65% and 6.56%, respectively.

Valuation MetricsWhile New Jersey Resources has moved to its 52-week high over the past few weeks, investors need to be asking, what is next for the company? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.

On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.

New Jersey Resources has a Value Score of B. The stock's Growth and Momentum Scores are B and B, respectively, giving the company a VGM Score of B.

In terms of its value breakdown, the stock currently trades at 16.8X current fiscal year EPS estimates, which is not in-line with the peer industry average of 17.6X. On a trailing cash flow basis, the stock currently trades at 11.2X versus its peer group's average of 9.4X. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.

Zacks RankWe also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, New Jersey Resources currently has a Zacks Rank of #2 (Buy) thanks to a solid earnings estimate revision trend.

Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if New Jersey Resources fits the bill. Thus, it seems as though New Jersey Resources shares could have potential in the weeks and months to come.

The Utilities group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. New Jersey Resources (NJR - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.

New Jersey Resources is a member of our Utilities group, which includes 110 different companies and currently sits at #14 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. New Jersey Resources is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for NJR's full-year earnings has moved 4% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the latest available data, NJR has gained about 24.9% so far this year. In comparison, Utilities companies have returned an average of 4.8%. This means that New Jersey Resources is outperforming the sector as a whole this year.

One other Utilities stock that has outperformed the sector so far this year is Sabesp (SBS - Free Report) . The stock is up 22.6% year-to-date.

The consensus estimate for Sabesp's current year EPS has increased 322.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).

Looking more specifically, New Jersey Resources belongs to the Utility - Gas Distribution industry, which includes 13 individual stocks and currently sits at #180 in the Zacks Industry Rank. Stocks in this group have gained about 5.3% so far this year, so NJR is performing better this group in terms of year-to-date returns.

On the other hand, Sabesp belongs to the Utility - Water Supply industry. This 11-stock industry is currently ranked #185. The industry has moved +3.7% year to date.

New Jersey Resources and Sabesp could continue their solid performance, so investors interested in Utilities stocks should continue to pay close attention to these stocks.

WALL, N.J.--(BUSINESS WIRE)--New Jersey Natural Gas (NJNG), the principal subsidiary of New Jersey Resources (NYSE: NJR), today announced it has submitted filings to the New Jersey Board of Public Utilities (NJBPU) that, taken together, provide customers with a 8.9% reduction in customer bills in advance of the 2026-2027 winter season – a $158 annual savings for the average residential customer – and rate stability while seeking recovery for investments in the continued delivery of safe, reliab.

Posted by Defense World Staff on Apr 27th, 2026

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has received an average rating of “Moderate Buy” from the seventeen ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $685.3077.

Several brokerages have commented on MDGL. Wolfe Research set a $579.00 price objective on shares of Madrigal Pharmaceuticals in a report on Tuesday, January 6th. The Goldman Sachs Group reiterated a “buy” rating and set a $571.00 target price on shares of Madrigal Pharmaceuticals in a report on Wednesday, January 14th. Citigroup reissued an “outperform” rating on shares of Madrigal Pharmaceuticals in a research report on Tuesday, January 20th. Zacks Research upgraded Madrigal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. Finally, Bank of America dropped their price target on Madrigal Pharmaceuticals from $570.00 to $529.00 and set a “neutral” rating on the stock in a research report on Friday, February 20th.

View Our Latest Research Report on Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Stock Performance NASDAQ:MDGL opened at $512.39 on Monday. The company has a quick ratio of 3.77, a current ratio of 4.01 and a debt-to-equity ratio of 0.56. Madrigal Pharmaceuticals has a 52 week low of $265.00 and a 52 week high of $615.00. The firm has a market capitalization of $11.75 billion, a P/E ratio of -39.81 and a beta of -1.00. The company has a fifty day moving average of $479.28 and a 200 day moving average of $502.84.

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) EPS for the quarter, missing the consensus estimate of $0.04 by ($2.61). Madrigal Pharmaceuticals had a negative return on equity of 43.76% and a negative net margin of 30.08%.The company had revenue of $321.08 million during the quarter, compared to analysts’ expectations of $310.36 million. During the same period in the prior year, the business posted ($2.71) earnings per share. The company’s revenue for the quarter was up 210.8% on a year-over-year basis. On average, research analysts predict that Madrigal Pharmaceuticals will post -5.22 earnings per share for the current year.

Insider Buying and Selling at Madrigal Pharmaceuticals In other Madrigal Pharmaceuticals news, General Counsel Shannon T. Kelley sold 360 shares of the firm’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $431.94, for a total transaction of $155,498.40. Following the completion of the transaction, the general counsel owned 12,138 shares of the company’s stock, valued at approximately $5,242,887.72. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO William John Sibold sold 1,663 shares of the company’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $431.94, for a total transaction of $718,316.22. Following the completion of the sale, the chief executive officer directly owned 161,829 shares in the company, valued at $69,900,418.26. This represents a 1.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 6,098 shares of company stock valued at $2,626,254. Company insiders own 21.50% of the company’s stock.

Institutional Investors Weigh In On Madrigal Pharmaceuticals A number of hedge funds and other institutional investors have recently bought and sold shares of MDGL. Flagship Harbor Advisors LLC purchased a new position in shares of Madrigal Pharmaceuticals during the fourth quarter valued at approximately $29,000. Aventura Private Wealth LLC bought a new stake in shares of Madrigal Pharmaceuticals in the 4th quarter worth approximately $36,000. Kemnay Advisory Services Inc. purchased a new stake in shares of Madrigal Pharmaceuticals in the 4th quarter worth approximately $39,000. Mather Group LLC. bought a new position in Madrigal Pharmaceuticals during the 3rd quarter valued at approximately $33,000. Finally, Global Retirement Partners LLC increased its position in Madrigal Pharmaceuticals by 221.7% during the 3rd quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 51 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Madrigal Pharmaceuticals Company Profile (Get Free Report)

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.

See Also Five stocks we like better than Madrigal Pharmaceuticals

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECritical Survey: Soho China (OTCMKTS:SOHOF) and Transcontinental Realty Investors (NYSE:TCI)

NEXT HEADLINE »Fox Factory Holding Corp. (NASDAQ:FOXF) Receives Average Recommendation of “Hold” from Analysts

The market expects Crinetics Pharmaceuticals, Inc. (CRNX - Free Report) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 7. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis company is expected to post quarterly loss of $1.22 per share in its upcoming report, which represents a year-over-year change of -17.3%.

Revenues are expected to be $7.55 million, up 1997.2% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 1.73% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for CRINETICS PHARM?For CRINETICS PHARM, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -9.02%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that CRINETICS PHARM will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that CRINETICS PHARM would post a loss of$1.37 per share when it actually produced a loss of -$1.29, delivering a surprise of +5.84%.

Over the last four quarters, the company has beaten consensus EPS estimates just once.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

CRINETICS PHARM doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAnother stock from the Zacks Medical - Drugs industry, Madrigal (MDGL - Free Report) , is soon expected to post loss of $3.28 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of +1.2%. Revenues for the quarter are expected to be $301.15 million, up 119.4% from the year-ago quarter.

The consensus EPS estimate for Madrigal has been revised 2% higher over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +61.01%.

When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Madrigal will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-PNPLA3, Arrowhead's clinical stage RNA interference (RNAi) therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH). “The early clinical data for ARO-PNPLA3 h.

CONSHOHOCKEN, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports first-quarter 2026 financial results and provides corporate updates.

Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript

May 07, 2026 16:05 ET  | Source: Madrigal Pharmaceuticals, Inc.

CONSHOHOCKEN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on May 1, 2026 to 47 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 5,312 shares of Madrigal’s common stock, 17,589 time-based restricted stock units and 1,839 performance-based restricted stock units. Options have an exercise price of $513.72 per share, which is equal to the closing price of the company’s common stock on the grant date. Options vest as follows: (i) 25% of the option shares will vest on the first anniversary of the grant date and (ii) 6.25% of the option shares will vest on each quarterly anniversary following the first anniversary of the grant date. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. Performance-based restricted stock units are earned based on the total shareholder return of Madrigal relative to a defined peer group over a three year period and, to the extent earned, will cliff vest in the first quarter of 2029. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, [email protected]

Media Contact
Christopher Frates, [email protected]

May 21, 2026 16:05 ET  | Source: Madrigal Pharmaceuticals, Inc.

CONSHOHOCKEN, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on May 15, 2026 to 15 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 5,308 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, [email protected]

Media Contact
Christopher Frates, [email protected]

Madrigal Pharmaceuticals, Inc. is a high-risk/high-reward play, focused solely on MASH with its first-in-class drug Rezdiffra. Rezdiffra's initial U.S. TAM is expanding, with diagnosis rates and label extensions potentially driving revenue to double-digit billions over the next decade. Competition from Novo Nordisk's Wegovy and upcoming Efruxifermin poses significant long-term risk, but MDGL enjoys a near-term lead and first-mover advantage.

June 04, 2026 16:05 ET  | Source: Madrigal Pharmaceuticals, Inc.

CONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 6,881 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, [email protected]

Media Contact
Christopher Frates, [email protected]

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Q1'26 Banner Image , /PRNewswire/ --

"2026 is off to a powerful start, with first quarter revenue climbing 12% to $3.8 billion. In an increasingly digital and AI-driven world, the global desire for authentic human connection has never been stronger. We are seeing a fundamental shift as fans prioritize the 'live' experience—the chance to be physically present with their favorite artists and share that energy with friends and fellow fans in a way a screen simply cannot replicate.

This cultural demand is driving record-breaking activity across our business. We have already booked over 85% of our large-venue shows for the year, with show counts up year-over-year across stadiums, arenas, and amphitheaters. Our momentum is clear: we have sold over 107 million tickets to date—an 11% increase—and Venue Nation is on track to grow fan attendance at our owned and operated venues by double-digits. As we continue to expand our global footprint to meet this growing demand for physical connection, we are well positioned for long-term compounding double-digit growth." –Michael Rapino, President and CEO

LIVE NATION PACES FOR DOUBLE-DIGIT GROWTH IN 2026 (1Q26 vs. 1Q25)

Revenue of $3.8 billion, up 12% Operating loss of $371 million, impacted by a $450 million legal accrual Adjusted operating income (AOI) of $371 million, up 9% with operating strength across all segments: Concerts AOI of $3 million with fan attendance of 24 million, up 7% Ticketing AOI of $256 million, driven by 81 million fee-bearing tickets, up 4% Sponsorship AOI up 21% to $165 million, driven by brand demand to connect with our global fan base Q1 deferred revenue for Concerts and Ticketmaster at record levels: Event-related deferred revenue of $6.6 billion, up 22%—largest deferred revenue balance in company history Ticketing deferred revenue of $368 million, up 29%, accounting for $5.5 billion in deferred ticketing gross transaction value (GTV) While 2026 operating income will be impacted by a $450 million legal accrual, on pace to grow adjusted operating income by double-digits this year GLOBAL ARTIST AND TOURING MOMENTUM ACCELERATE 2026 CONCERTS PERFORMANCE 

Revenue of $2.8 billion, up 12% vs. 1Q25 Q1 AOI of $3 million and $12 million on a constant currency basis Over 85% of 2026 large venue shows booked (confirmed and offer-in) through the end of April, pacing up high-single digits so far this year, with stadium, arena, and amphitheater show count all up year-on-year Tickets sold through the end of April for 2026 Live Nation concerts up 11% to over 107 million, with consistent double-digit growth across key venue types—stadiums, arenas, amphitheaters, and festivals Full year fan attendance projected to grow high-single digits with timing shifts due to venue mix: Top driver of Q2 fan growth expected to be third-party arenas 70% of amphitheater fan growth expected to occur in Q3, in line with the summer calendar All stadium fan growth will occur in the second half For the full year, Concerts on track to deliver double-digit AOI growth with margins positioned to build on last year's VENUE NATION EXPANDS GLOBAL FOOTPRINT AND DELIVERS DEEPER FAN ENGAGEMENT 

Venues opened in 2025 on track to reach their run-rate annual AOI across Concerts and Sponsorship by 2028, delivering 20%+ IRRs: TD Coliseum in Hamilton, Canada delivered a strong Q1 with show count up double-digits and set to deliver 80 shows for the full year—surpassing initial projections At Rogers Stadium in Toronto, projected show count for the full-year is up 40% compared to its inaugural year in 2025 Ongoing roll out of premium hospitality, Live Nation's Vinyl Room, delivering strong results so far this year with onsite spending at the Hollywood Palladium over $100 per fan, and up 30% per fan at Ziggo Dome in Amsterdam Venue Nation on track to grow fans at owned or operated venues by double-digits in 2026: Recently completed three acquisitions: Movistar Arena Santiago, Unipol Forum in Milan, and IMPACT Arena in Bangkok, with a cumulative annual fan capacity of approximately four million 2026 major projects include two U.S. amphitheaters and one stadium in Guadalajara, Mexico 2026 preopening costs for all venues under development expected to remain at approximately $50 million Venues opening in 2026 are projected to reach their run-rate annual AOI across Concerts and Sponsorship by 2029, continuing to deliver 20%+ IRRs CONCERTS DEMAND DRIVES TICKETMASTER STRENGTH IN Q1 (vs. 1Q25 unless otherwise noted)

Revenue of $765 million, up 10% AOI of $256 million, up 1% $30 million in expenses related to legal and operational improvements Primary GTV grew 14%, with concerts delivering most of the growth Ticketmaster well positioned for sustained long-term growth: Ticketmaster total fee-bearing tickets transacted through April for 2026 up 9% to 138 million, with GTV of $17 billion, up 15% Primary fee-bearing ticket volume expected to grow mid-single digits for the full year  Ongoing efforts to reduce scalper activity expected to impact full-year Ticketmaster AOI by mid-single digits Full year AOI margin expected to be similar to last year THE POWER OF PRESENCE: BRANDS PRIORITIZE AUTHENTIC CONNECTION AS GLOBAL SPONSORSHIP ACTIVITY REACHES NEW HEIGHTS (vs. 1Q25 unless otherwise noted)

Revenue of $259 million, up 20% AOI of $165 million, up 21%, reflecting the strength of international festivals in South America and our growing venue portfolio 85% of 2026 sponsorship commitments booked as of end of April, up double-digits AOI expected to grow double-digits for the full year, driven by venue portfolio expansion including naming rights across major arenas and festivals globally Full year AOI margin expected to be similar to last year CAPITAL ALLOCATION SUPPORTS VENUE EXPANSION AND LONG-TERM GROWTH 

Q1 capital expenditures totaled $249 million; full year spend expected to be $1.1 to $1.2 billion:  Approximately $800 to $850 million of total capex is for venue expansion and enhancement projects Venue investment cash requirements expected to be reduced by approximately $250 million from funding by joint-venture partners, sponsorship agreements, and other sources Additional capex allocated to our ticketing and sponsorship growth initiatives, as well as ongoing maintenance at our venues Full year AOI to free cash flow—adjusted conversion expected to be in line with or higher than 2025 CONTINUED TO BOLSTER OUR BALANCE SHEET IN Q1

Cash and cash equivalents of $9.1 billion, up from $7.2 billion last year and free cash of $1.7 billion, up from $1.1 billion last year Leverage stands at 3.6x, in line with historical levels, with a weighted average cost of debt of 4.2% In April, raised approximately €610 million in long-term debt at 5.5% through an investment grade financing vehicle backed by a portfolio of major venues FULL-YEAR INCOME STATEMENT DETAILS (vs. FY25)

Depreciation and amortization expected to grow 12-15% Net interest expense is expected to be $280 million Income tax expense is expected to be 15-20% of AOI, with cash taxes projected to be 80% of that amount Below the line items: A $450 million legal accrual impacted Q1 operating income and earnings per share by $(1.93) Noncontrolling interest expense is expected to grow 25% driven by strong performance across our global partnerships Accretion expense is expected to be $160-180 million 2026 share count not expected to change materially from 2025 Compare Our Operating Results to Past Quarters In The Trended Results Grid:
https://investors.livenationentertainment.com/financial-information/financial-results

The company will webcast a teleconference today, May 5, 2026, at 2:00 p.m. Pacific Time to discuss its financial performance, operational matters and potentially other material developments. Interested parties should visit the "News / Events" section of the company's website at investors.livenationentertainment.com to listen to the webcast. Supplemental statistical and financial information to be provided on the call, if any, will be posted to the "Financial Info" section of the website. A replay of the webcast will also be available on the Live Nation website. The link to the 1Q26 Trended Results Grid is provided above for convenience and such grid is not a part of, or incorporated into, this press release or any SEC filings that include this press release.

Notice Regarding Financial Statements
The company has provided certain financial statements at the end of this press release for reference. These financial statements should be read in conjunction with the full financial statements, and the notes thereto, set forth in the company's Annual Report on Form 10-Q for the quarter ended March 31, 2026 to be filed with the Securities and Exchange Commission today and available on the SEC's website at sec.gov.

About Live Nation Entertainment:
Live Nation Entertainment, Inc. (NYSE: LYV) is the world's leading live entertainment company comprised of global market leaders: Ticketmaster, Live Nation Concerts, and Live Nation Media & Sponsorship. For additional information, visit investors.livenationentertainment.com.

FINANCIAL HIGHLIGHTS – FIRST QUARTER

(unaudited; $ in millions)

Q1 2026
Reported

Q1 2025

Reported

Change

Q1 2026

Currency
Impacts

Q1 2026
Constant
Currency

Change at
Constant
Currency

Revenue

Concerts

$      2,775.5

$       2,484.1

12 %

$     (89.9)

$      2,685.6

8 %

Ticketing

765.0

694.7

10 %

(19.0)

746.0

7 %

Sponsorship & Advertising

258.6

216.1

20 %

(12.3)

246.3

14 %

Other and Eliminations

(6.1)

(12.8)

*

0.0

(6.1)

*

$      3,793.0

$       3,382.1

12 %

$    (121.2)

$      3,671.8

9 %

Consolidated Operating

Income (Loss)

$       (370.5)

$         114.8

*

$       12.7

$       (357.8)

*

Adjusted Operating Income (Loss)

Concerts

$           2.9

$            6.6

(56) %

$        8.9

$          11.8

79 %

Ticketing

255.6

253.1

1 %

(6.6)

249.0

(2) %

Sponsorship & Advertising

164.6

136.0

21 %

(9.5)

155.1

14 %

Other and Eliminations

(4.2)

(5.9)

*

0.1

(4.1)

*

Corporate

(47.9)

(48.7)

2 %

0.0

(47.9)

2 %

$        371.0

$         341.1

9 %

$       (7.1)

$        363.9

7 %

* Percentages are not meaningful

Reconciliation of Operating Income (Loss) to Adjusted Operating Income

(unaudited; $ in millions)

Q1 2026

Q1 2025

Operating Income (Loss)

$            (370.5)

$              114.8

Acquisition expenses

69.4

29.7

Amortization of non-recoupable ticketing contract advances

26.0

24.7

Depreciation and amortization

169.3

149.5

Gain on sale of operating assets

(6.0)

(2.2)

Governmental Investigations and Litigation

450.0

—

Stock-based compensation expense

32.8

24.6

Adjusted Operating Income

$             371.0

$              341.1

Reconciliations of Certain Non-GAAP Measures to Their Most Directly Comparable GAAP Measures

(unaudited; $ in millions)

Reconciliation of Free Cash Flow — Adjusted to Net Cash Provided by Operating Activities

Q1 2026

Q1 2025

Net cash provided by operating activities

$            2,338.8

$            1,321.3

Changes in operating assets and liabilities (working capital)

(2,546.1)

(1,056.6)

Governmental Investigations and Litigation

450.0

—

Free cash flow from earnings

$              242.7

$              264.7

Less: Maintenance capital expenditures

(30.0)

(14.9)

          Distributions to noncontrolling interests

(38.0)

(33.7)

Free cash flow — adjusted

$              174.7

$              216.1

Net cash used in investing activities

$             (417.7)

$             (217.4)

Net cash provided by (used in) financing activities

$              117.5

$             (173.2)

Reconciliation of Free Cash to Cash and Cash Equivalents

($ in millions)

March 31,
2026

March 31,
2025

Cash and cash equivalents

$               9,077.8

$               7,158.7

Short-term investments

43.8

64.5

Client cash

(1,810.8)

(1,559.9)

Deferred revenue — event-related

(6,601.7)

(5,395.9)

Accrued artist fees

(173.8)

(125.5)

Collections on behalf of others

(164.5)

(140.5)

Prepaid expenses — event-related

1,336.6

1,117.5

Free cash

$               1,707.4

$               1,118.9

Forward-Looking Statements, Non-GAAP Financial Measures and Reconciliations:

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to statements regarding the company's prospects for a record year in 2026 with anticipated double-digit growth, and its positioning for long-term compounding double-digit growth; expectations for operating income and adjusted operating income levels in 2026; expected Venue Nation fan growth at owned or operated venues in 2026; anticipated full year adjusted operating income growth for the company's concerts business, as well as expected full year fan attendance and anticipated shifts in seasonality by venue type, and full year margin expectations; pacing for venues opened in 2025 to reach their run-rate annual adjusted operating income across concerts and sponsorship by 2028 as well as expected IRRs, as well as expectations for show count at these venues; expectations for Venue Nation fan growth at owned or operated venues for 2026 versus 2025; expected 2026 Venue Nation new builds; anticipated 2026 preopening costs for venues under development; the projection that venues opening in 2026 will reach their run-rate annual adjusted operating income across concerts and sponsorship by 2029, as well as expected IRRs; Ticketmaster's positioning for sustained long-term growth, including full year expectations for growth in primary fee-bearing tickets, the impact to full year adjusted operating income from ongoing efforts to reduce scalper activity, and full year 2026 adjusted operating income margin expectations; expectations for full year 2026 adjusted operating income growth in the company's sponsorship & advertising business, as well as full year adjusted operating income margin for the business; expected capital expenditure levels in 2026; expectations for full year 2026 adjusted operating income to free cash flow—adjusted conversion rates; expectations for full year 2026 levels of depreciation and amortization, net interest expense, income tax expense as a percentage of adjusted operating income, accretion expense, noncontrolling interest expense, and share count.

Live Nation wishes to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements, including but not limited to operational challenges in achieving strategic objectives and executing on the company's plans, the risk that the company's markets do not evolve as anticipated, the potential impact of any economic slowdown and operational challenges associated with selling tickets and staging events.

Live Nation refers you to the documents it files from time to time with the U.S. Securities and Exchange Commission, or SEC, specifically the section titled "Item 1A. Risk Factors" of the company's most recent Annual Report filed on Form 10-K, and Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K, which contain and identify other important factors that could cause actual results to differ materially from those contained in the company's projections or forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date on which they are made. All subsequent written and oral forward-looking statements by or concerning Live Nation are expressly qualified in their entirety by the cautionary statements above. Live Nation does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise.

This press release contains certain non-GAAP financial measures as defined by SEC Regulation G. A reconciliation of each such measure to its most directly comparable GAAP financial measure, together with an explanation of why management believes that these non-GAAP financial measures provide useful information to investors, is provided herein.

Adjusted Operating Income (Loss), or AOI, is a non-GAAP financial measure that we define as operating income (loss) before certain acquisition expenses (including ongoing legal costs stemming from the Ticketmaster merger, changes in the fair value of accrued acquisition-related contingent consideration obligations, and acquisition-related severance and compensation), amortization of non-recoupable ticketing contract advances, depreciation and amortization (including goodwill impairment), loss (gain) on disposal of operating assets, and stock-based compensation expense. Due to the significant and non-recurring nature of the matters, we also exclude from AOI the impact of realized liabilities for settlements and expenses for regulatory compliance matters associated with the provision for losses arising from certain significant governmental investigations and litigations under ASC 450 - Contingencies, which are described under the heading "Governmental Investigations and Litigation" in Note 6 of the Notes to the Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. Except as described above, ongoing legal costs associated with defense of these claims, such as attorney fees, are not excluded from AOI. We use AOI to evaluate the performance of our operating segments. We believe that information about AOI assists investors by allowing them to evaluate changes in the operating results of our portfolio of businesses separate from non-operational factors that affect net income (loss), thus providing insights into both operations and the other factors that affect reported results. AOI is not calculated or presented in accordance with GAAP. A limitation of the use of AOI as a performance measure is that it does not reflect the periodic costs of certain amortizing assets used in generating revenue in our business. Accordingly, AOI should be considered in addition to, and not as a substitute for, operating income (loss), net income (loss), and other measures of financial performance reported in accordance with GAAP. Furthermore, this measure may vary among other companies; thus, AOI as presented herein may not be comparable to similarly titled measures of other companies.

AOI margin is a non-GAAP financial measure that we calculate by dividing AOI by revenue. We use AOI margin to evaluate the performance of our operating segments. We believe that information about AOI margin assists investors by allowing them to evaluate changes in the operating results of our portfolio of businesses separate from non-operational factors that affect net income (loss), thus providing insights into both operations and the other factors that affect reported results. AOI margin is not calculated or presented in accordance with GAAP. A limitation of the use of AOI margin as a performance measure is that it does not reflect the periodic costs of certain amortizing assets used in generating revenue in our business. Accordingly, AOI margin should be considered in addition to, and not as a substitute for, operating income (loss) margin, and other measures of financial performance reported in accordance with GAAP. Furthermore, this measure may vary among other companies; thus, AOI margin as presented herein may not be comparable to similarly titled measures of other companies.

Constant Currency is a non-GAAP financial measure when applied to a GAAP financial measure. We calculate currency impacts as the difference between current period activity translated using the current period's currency exchange rates and the comparable prior period's currency exchange rates. We present constant currency information to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency rate fluctuations.

Free Cash Flow — Adjusted, or FCF, is a non-GAAP financial measure that we define as net cash provided by (used in) operating activities less changes in operating assets and liabilities, less maintenance capital expenditures, less distributions to noncontrolling interest partners. We use FCF among other measures, to evaluate the ability of operations to generate cash that is available for purposes other than maintenance capital expenditures. We believe that information about FCF provides investors with an important perspective on the cash available to service debt, make acquisitions, and for revenue generating capital expenditures. FCF is not calculated or presented in accordance with GAAP. A limitation of the use of FCF as a performance measure is that it does not necessarily represent funds available for operations and is not necessarily a measure of our ability to fund our cash needs. Accordingly, FCF should be considered in addition to, and not as a substitute for, net cash provided by (used in) operating activities and other measures of financial performance reported in accordance with GAAP. Furthermore, this measure may vary among other companies; thus, FCF as presented herein may not be comparable to similarly titled measures of other companies.

Free Cash is a non-GAAP financial measure that we define as cash and cash equivalents less ticketing-related client funds, less event-related deferred revenue, less accrued expenses due to artists and cash collected on behalf of others, plus event-related prepaids. We use free cash as a proxy for how much cash we have available to, among other things, optionally repay debt balances, make acquisitions and fund revenue generating capital expenditures. Free cash is not calculated or presented in accordance with GAAP. A limitation of the use of free cash as a performance measure is that it does not necessarily represent funds available from operations and it is not necessarily a measure of our ability to fund our cash needs. Accordingly, free cash should be considered in addition to, and not as a substitute for, cash and cash equivalents and other measures of financial performance reported in accordance with GAAP. Furthermore, this measure may vary among other companies; thus, free cash as presented herein may not be comparable to similarly titled measures of other companies.

LIVE NATION ENTERTAINMENT, INC.

CONSOLIDATED BALANCE SHEETS

(unaudited)

March 31,
2026

December 31,
2025

(in thousands)

ASSETS

Current assets

    Cash and cash equivalents

$          9,077,847

$          7,094,200

    Accounts receivable, less allowance of $78,255 and $73,912, respectively

1,965,296

2,009,055

    Prepaid expenses

2,217,054

1,453,732

    Other current assets

381,342

417,405

Total current assets

13,641,539

10,974,392

Property, plant and equipment, net

3,664,231

3,415,771

Operating lease assets

1,910,332

1,869,753

Intangible assets

    Definite-lived intangible assets, net

1,071,290

1,078,453

    Indefinite-lived intangible assets, net

368,961

369,015

Goodwill

2,933,243

2,889,178

Long-term advances

667,912

631,071

Other long-term assets

1,810,584

1,684,900

Total assets

$         26,068,092

$         22,912,533

LIABILITIES AND EQUITY

Current liabilities

    Accounts payable, client accounts

$          2,174,981

$          1,941,389

    Accrued expenses and accounts payable

3,562,342

3,555,811

    Deferred revenue

7,410,720

4,461,959

    Current portion of long-term debt, net

1,800,776

587,630

    Other current liabilities

467,757

482,061

Total current liabilities

15,416,576

11,028,850

Long-term debt, net

6,709,420

7,612,018

Long-term operating lease liabilities

2,073,207

2,036,974

Other long-term liabilities

435,347

415,844

Commitments and contingent liabilities

Redeemable noncontrolling interests

951,724

924,472

Stockholders' equity

    Common stock

2,333

2,328

    Additional paid-in capital

1,405,279

1,455,925

    Accumulated deficit

(1,431,082)

(1,041,978)

    Cost of shares held in treasury

(30,396)

(30,396)

    Accumulated other comprehensive loss

(85,538)

(114,872)

Total Live Nation stockholders' equity

(139,404)

271,007

Noncontrolling interests

621,222

623,368

Total equity

481,818

894,375

Total liabilities and equity

$         26,068,092

$         22,912,533

LIVE NATION ENTERTAINMENT, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

Three Months Ended March 31,

2026

2025

(in thousands except share and

per share data)

Revenue

$           3,793,029

$           3,382,117

Operating expenses:

Direct operating expenses

2,478,458

2,254,937

Selling, general and administrative expenses

961,519

778,922

Depreciation and amortization

169,296

149,455

Gain on disposal of operating assets

(6,022)

(2,202)

Corporate expenses

560,294

86,236

Operating income (loss)

(370,516)

114,769

Interest expense

90,522

80,343

Interest income

(39,467)

(34,061)

Equity in losses (earnings) of nonconsolidated affiliates

2,883

(479)

Other expense (income), net

(12,351)

2,953

Income (loss) before income taxes

(412,103)

66,013

Income tax expense (benefit)

(32,085)

19,711

Net income (loss)

(380,018)

46,302

Net income attributable to noncontrolling interests

9,086

23,099

Net income (loss) attributable to common stockholders of Live Nation

$            (389,104)

$               23,203

Basic and diluted net loss per common share available

to common stockholders of Live Nation

$                (1.85)

$                (0.32)

Weighted average common shares outstanding:

Basic and diluted

232,400,991

231,220,841

Reconciliation to net loss available to common stockholders of Live Nation:

Net income (loss) attributable to common stockholders of Live Nation

$            (389,104)

$               23,203

Accretion of redeemable noncontrolling interests

(41,279)

(98,094)

Net loss available to common stockholders of Live Nation—basic and diluted

$            (430,383)

$             (74,891)

LIVE NATION ENTERTAINMENT, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

Three Months Ended March 31,

2026

2025

(in thousands)

CASH FLOWS FROM OPERATING ACTIVITIES

Net income (loss)

$        (380,018)

$          46,302

Reconciling items:

Depreciation

99,565

89,462

Amortization of definite-lived intangibles

69,731

59,993

Amortization of non-recoupable ticketing contract advances

26,020

24,722

Deferred income taxes

(44,693)

4,271

Amortization of debt issuance costs and discounts

5,150

3,684

Stock-based compensation expense

32,777

24,550

Unrealized changes in fair value of contingent consideration

10,409

1,169

Equity in losses of nonconsolidated affiliates, net of distributions

4,553

3,480

Provision for uncollectible accounts receivable

(1,224)

3,574

Gain on mark-to-market of investments in nonconsolidated affiliates and crypto assets

(6,189)

(5,467)

Loss (gain) on forward currency exchange contracts

(17,306)

13,361

Other, net

(6,002)

(4,485)

Changes in operating assets and liabilities, net of effects of acquisitions and dispositions:

Decrease (increase) in accounts receivable

70,629

(70,535)

Increase in prepaid expenses and other assets

(783,967)

(592,946)

Increase (decrease) in accrued expenses, accounts payable and other liabilities

281,040

(545,945)

Increase in deferred revenue

2,978,360

2,266,061

Net cash provided by operating activities

2,338,835

1,321,251

CASH FLOWS FROM INVESTING ACTIVITIES

Advances of notes receivable

(1,944)

(6,403)

Collections of notes receivable

5,920

9,375

Investments made in nonconsolidated affiliates

(9,649)

(3,887)

Purchases of property, plant and equipment

(308,978)

(170,791)

Cash paid for acquisition of right-of-use assets

—

(20,800)

Cash paid for acquisitions, net of cash acquired

(113,203)

(31,346)

Other, net

10,115

6,457

Net cash used in investing activities

(417,739)

(217,395)

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from debt, net of debt issuance costs

226,161

11,059

Payments on debt including extinguishment costs

(6,611)

(86,828)

Contributions from noncontrolling interests

11,349

4,612

Distributions to noncontrolling interests

(38,000)

(33,742)

Purchases of noncontrolling interests, net

(25,882)

(4,496)

Proceeds from exercise of stock options

783

2,606

Taxes paid for net share settlement of equity awards

(47,930)

(65,009)

Payments for deferred and contingent consideration

(1,530)

(1,242)

Other, net

(859)

(150)

Net cash provided by (used in) financing activities

117,481

(173,190)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

(54,613)

131,471

Net increase in cash, cash equivalents and restricted cash

1,983,964

1,062,137

Cash, cash equivalents and restricted cash at beginning of period

7,106,986

6,106,109

Cash, cash equivalents and restricted cash at end of period

$       9,090,950

$       7,168,246

SOURCE Live Nation Entertainment

The company posted a first-quarter loss of $389.1 million, compared with a profit of $23.2 million a year earlier.

Live Nation (LYV) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.32 per share a year ago.

Live Nation Entertainment (LYV 0.25%) earned an encore on Wednesday. The Ticketmaster parent technically posted a mixed earnings report, hampered by a large legal expense. Investors applauded the results anyway, as management expects stronger profits in the upcoming quarters.

The stock closed Wednesday's trading at a 6.7% gain. It reached a peak of 8% near noon ET.

Today's Change

(

-0.25

%) $

-0.43

Current Price

$

171.90

Live Nation's Q1 by the numbers Q1 revenues rose 12% year-over-year to $3.8 billion. The analyst community had expected roughly $3.6 billion.

On the bottom line, Live Nation's net losses deepened from $0.32 to $1.85 per share, well below the Street estimate of $0.36 per share. However, these generally accepted accounting practices (GAAP) figures include a $450 million charge for legal fees. The company doesn't publish adjusted earnings figures, but if I do the math myself, Live Nation would have seen positive earnings of approximately $0.08 per share without those costly legal fees.

Image source: Getty Images.

Legal drama aside, ticket sales look strong Mind you, Live Nation hasn't entirely closed the books on that large legal expense. The company has appealed several pieces of the underlying jury verdict, so the lawsuit that the Department of Justice launched in May 2024 is still in play.

Looking beyond the courtroom drama, Live Nation sees healthy concert ticket sales as the summer season draws near. In particular, the low-priced amphitheater format is off to a strong start, which makes sense in this era of budget-pinching inflation.

"Consumers still consider the live show very important in their social calendar for the year," CEO Michael Rapino said on the earnings call. "We have seen broad, strong demand across the board."

With ticket sales up double digits and most large-venue shows already booked for 2026, Live Nation's core business appears healthy. The legal saga may drag on, but investors seem willing to look past it for now.

Anders Bylund has no position in any of the stocks mentioned. The Motley Fool recommends Live Nation Entertainment. The Motley Fool has a disclosure policy.

MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 324

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

Live Nation Entertainment, Inc. (LYV) Presents at J.P. Morgan 54th Annual Global Technology, Media and Communications Conference Transcript

Warner Bros. Discovery (WBD) shares slipped on Friday after a report said Paramount Skydance (PSKY) hired a prominent lawyer to help defend its planned takeover

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Live Nation Entertainment, Inc. (NYSE: LYV) breached their fiduciary duties to shareholders.

If you currently own Live Nation stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Across select amphitheaters nationwide, Lowe's is giving loyalty members exclusive perks and new ways to connect through live music all year long

, /PRNewswire/ -- Lowe's is bringing MyLowe's Rewards* and MyLowe's Pro Rewards* members exclusive live music experiences through a new multi-year partnership with Live Nation. Members can access exclusive concert perks throughout the season, including discounted kids tickets† with purchase of an adult lawn ticket, complimentary lawn chair rentals at select shows for the first fifty eligible members^ and sweepstakes for a chance to win free tickets all year long. Helping members get more from the experiences they value most, these exclusive offers unlock more ways to enjoy live music with friends and family.

Lowe’s is bringing MyLowe’s Rewards and MyLowe’s Pro Rewards members exclusive live music experiences through a new multi-year partnership with Live Nation. The partnership also makes Lowe's the first presenting partner of a new amphitheater tailgate experience Live Nation is introducing at select venues this summer. Creating a new way for fans to kick off their night out, the spaces will bring together live entertainment, food and beverage offerings and programming from select Lowe's vendor partners, with specific experiences tailored by venue at North Island Credit Union Amphitheatre, Ruoff Music Center and Jiffy Lube Live. Tailgates begin when general parking lots open, with space available on a first-come, first-served basis.

Through the partnership, Lowe's is meeting customers where they already love to spend time, creating new ways to connect through live music and shared experiences. Designed to deliver both everyday value and meaningful moments, rewards members also get additional ways to save and earn. The free MyLowe's Rewards and MyLowe's Pro Rewards programs, now with more than 30 million members combined, offer personalized savings, bonus points and access to exclusive products and seasonal perks.

Each year, millions of fans return to amphitheaters as part of their summer routines, with 80% saying their local live music venues play a role in the moments they look forward to most with family and friends.

"Music is one of the things that brings people together — families, friends and entire communities — and we love being part of the moments people look forward to all year long," said Jen Wilson, Lowe's senior vice president and chief marketing officer. "Through this partnership, we're leveraging live music to reach new and younger audiences while giving our existing members exclusive perks that make these experiences even more rewarding. It's all about helping families make the most of a night out and rewarding loyalty by showing up in meaningful ways beyond the home."

"When fans come out to a show, they want the whole night to feel special," said Russell Wallach, Global President, Media & Sponsorship at Live Nation. "Jen and the Lowe's team really understood that from the start. We saw an opportunity to build around the moments fans already love during the summer and create more ways for people to spend time together before the music even starts through our new tailgate spaces presented by Lowe's."

MyLowe's Rewards and MyLowe's Pro Rewards members can access these benefits starting this summer at participating amphitheaters, with additional perks to come throughout the year. Learn more at https://www.lowes.com/concertperks.

*Loyalty Programs subject to Terms & Conditions. See Lowes.com/Terms for full program details. Subject to change. MyLowe's Rewards Program subject to terms & conditions. Visit Lowes.com/Terms for details. Subject to change.   
†MyLowe's Rewards members who receive a unique code via MyLowe's Rewards communications may purchase "2 for 1" lawn tickets (1 adult ticket and 1 child ticket) to participating concerts, while supplies last. For each participating concert, the first fifty (50) Members 18 years of age or older who enter their code at ticket check out will be able to purchase two (2) discounted tickets. Must purchase two (2) tickets and enter an eligible code to receive the offer. Ticket prices are "all in" pricing. The child using a ticket must be 12 years of age or younger and accompanied at all times at the concert by a parent or legal guardian. Offer is limited to one (1) per customer. Any customer found violating the terms of the Offer may be disqualified. Offer cannot be combined with other offers or discounts, cannot be used on past purchases, and is void where prohibited.
^The first fifty (50) MyLowe's Rewards members ("Members") at each participating concert who go to the chair rental location and show their Member ID in the Lowe's app will receive a complimentary chair rental, while supplies last. Members must be 18 years of age or older. Must have a valid concert ticket to claim offer. Offer is limited to one (1) complimentary chair per Member per concert. Offer has no cash value and is void where prohibited. Check venue policy for chair usage terms and return instructions. Sponsor may cancel or suspend the Offer at any time without notice or liability. Sponsor: Lowe's Companies, Inc. 

About Live Nation Entertainment
Live Nation Entertainment (NYSE: LYV) is the world's leading live entertainment company comprised of global market leaders: Ticketmaster, Live Nation Concerts, and Live Nation Sponsorship. For additional information, visit www.livenationentertainment.com.

About Lowe's
Lowe's Companies, Inc. (NYSE: LOW) is a FORTUNE® 100 home improvement company with total fiscal year 2025 sales of more than $86 billion. Lowe's employs approximately 300,000 associates and operates over 1,750 home improvement stores, 540 branches and 120 distribution centers. Based in Mooresville, N.C., Lowe's supports the communities it serves through programs focused on creating safe, affordable housing, improving community spaces, helping to develop the next generation of skilled trade experts and providing disaster relief to communities in need. For more information, visit Lowes.com.

Contact:
Lowe's Media Team
Amanda Caskey
[email protected]

Live Nation Media Team
Danika Azzarelli
[email protected]

SOURCE Lowe's Companies, Inc.

TAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced that upon the market opening on March 24, 2026, the Company’s Class A Ordinary Shares will be traded on The Nasdaq Stock Market under the symbol “SXTC”.

On July 28, 2025, the Company held a special meeting of shareholders (the “Meeting”). At the Meeting, shareholders approved a change to the Company’s authorized share capital to establish a dual class share structure by (i) creating a new class of shares consisting of unlimited Class B Ordinary Shares, which entitle the holder to fifty (50) votes per Class B Ordinary Share on any resolution of shareholders, and (ii) designating the Company’s existing Ordinary Shares as Class A Ordinary Shares, each with no par value (the “Share Re-classification”). The Share Re-classification became effective upon filing of the Amended and Restated Memorandum and Articles of Association with the Companies Registry of the British Virgin Islands by the Company. The Company is authorized to issue an unlimited number of shares, divided into two Classes consisting of Class A Ordinary Shares with no par value and Class B Ordinary Shares with no par value.

Upon the effectuation of the Share Re-classification, shareholders holding shares through a bank, broker or other nominee will have their shares automatically adjusted to reflect the Share Re-classification.  Beneficial holders may contact their bank, broker or nominee for more information. Please direct any questions to your broker or the Company's transfer agent, Transhare Corporation, by calling +1 303-662-1122.

About China SXT Pharmaceuticals, Inc.

Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit www.sxtchina.com.

Safe Harbor Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. The Company’s actual results may differ materially from those expressed in any forward-looking statements as a result of various factors and uncertainties. The reports filed by the Company with the Securities and Exchange Commission discuss these and other important factors and risks that may affect the Company’s business, results of operations and financial conditions. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Feng Zhou, Chief Executive Officer

Email: [email protected]

Unprecedented demand for natural colors spurs significant capital investment in Sensient's Natural Color Manufacturing Capacity, including expansion of largest production site in St. Louis, Missouri

, /PRNewswire/ -- On March 23rd, Sensient Food Colors, a division of Sensient Technologies (NYSE: SXT), officially celebrated the commencement of a major expansion at its largest natural color plant, which is located in St. Louis, Missouri. The expansion, coined Project Prism, is one of the many capital investments planned by Sensient to support the food and beverage industry's rapid transition away from artificial colors in the United States. Sensient expects to spend up to $250 million in the coming years to expand its natural color manufacturing capacity, supply chain, and personnel.

Sensient Project Prism Groundbreaking Event, March 2026

Sensient Project Prism Groundbreaking Event, March 2026

Sensient Project Prism Groundbreaking Event, March 2026

Sensient Project Prism Groundbreaking Event, March 2026

Sensient Project Prism Groundbreaking Event, March 2026

Sensient Project Prism Groundbreaking Event, March 2026

Sensient Project Prism Groundbreaking Event, March 2026

The St. Louis natural colors plant expansion is being done in partnership with Burns & McDonnell and will add 28,800 square feet of specialized processing and production capacity onto Sensient's existing 500,000 square foot manufacturing facility.

"Sensient has taken a defining role in accelerating the industry's transition to natural color solutions. We are reinforcing our leadership position by making significant investments in capacity and infrastructure to facilitate the natural color conversion in the United States. The groundbreaking ceremony marks a pivotal milestone in our mission to better serve customers and lead this industry-wide change," stated Sensient Colors President, Steve Morris.

The groundbreaking ceremony was attended by distinguished guests, including Missouri Lieutenant Governor David Wasinger, and the President and CEO of the Regional Business Council of St. Louis, Karen Branding, and received coverage from local media outlets.

Sensient's St. Louis plant expansion is a testament to the company's service-first model and commitment to customer satisfaction and natural color innovation.

About Sensient Colors LLC

Sensient Colors brings life to products, adding color and visual enjoyment to food and beverage applications worldwide. Offering unparalleled color innovation and proprietary technologies, Sensient Food Colors applies industry defining color expertise, enhancing brand value through premium sensory appeal and performance. Sensient Colors LLC is headquartered in St. Louis, Missouri.

About Sensient Technologies

Sensient Technologies Corporation is a leading global manufacturer and marketer of colors, flavors, and other specialty ingredients. Sensient uses advanced technologies and robust global supply chain capabilities to develop specialized solutions for food and beverages, as well as products that serve the pharmaceutical, nutraceutical, and personal care industries. Sensient's customers range in size from small entrepreneurial businesses to major international manufacturers representing some of the world's best-known brands. Sensient is headquartered in Milwaukee, Wisconsin. www.sensient.com

Media Contact Information: 

Brittany V. Jones
Sensient Food Colors
Director of Marketing
[email protected]
+1 (557) 213-7278

SOURCE Sensient Food Colors